Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
Vet Parasitol Reg Stud Reports ; 24: 100546, 2021 04.
Article in English | MEDLINE | ID: mdl-34024364

ABSTRACT

South American opossums of the order Didelphimorphia are considered sentinels for zoonotic infections and environmental diseases, such as for Chagas disease caused by Trypanosoma cruzi. Nevertheless, there is a paucity of data regarding protozoan diseases such Toxoplasma gondii and Neospora caninum in Neotropical marsupials; despite these pathogens have been considered threats to some marsupial species. The aim of this study was to determine whether Didelphis albiventris and Philander frenatus opossums from southern Brazil had been previously exposed to T. cruzi, T. gondii or N. caninum. Opossum samples were obtained by live-trapping of free-ranging animals and collection at wildlife rehabilitation centers in Rio Grande do Sul (RS) state, Brazil. The detection of anti-T. cruzi and anti-T. gondii antibodies was performed by indirect hemagglutination and anti-N. caninum antibodies by competitive enzyme-linked immunosorbent assay. In total, samples were collected from 76 marsupials from nine municipalities in RS state, including 69 D. albiventris (white-eared opossum), and seven were P. frenatus (southern four-eyed opossum). For T. cruzi, 11% were seropositive, and for T. gondii 26% were seropositive. None of the marsupials sampled here were seropositive for N. caninum. Risk factor analysis showed that free-living animals were about five-fold more likely to be infected by T. gondii than were rescued animals. Our study showed the exposure of Neotropical marsupials (D. albiventris and P. frenatus) to protozoan pathogens T. cruzi and T. gondii, while no evidence of N. caninum exposure was found. The set of results presented here may have an effect on ecology and conservation of the studied species and may also indicate possible sentinels of these pathogen circulation.


Subject(s)
Coccidiosis , Didelphis , Neospora , Toxoplasma , Toxoplasmosis, Animal , Trypanosoma cruzi , Animals , Antibodies, Protozoan , Brazil/epidemiology , Coccidiosis/epidemiology , Coccidiosis/veterinary , Seroepidemiologic Studies , Toxoplasmosis, Animal/epidemiology
2.
Mol Psychiatry ; 22(11): 1594-1603, 2017 11.
Article in English | MEDLINE | ID: mdl-28220044

ABSTRACT

Cannabis-induced acute psychotic-like states (CIAPS) represent a growing health issue, but their underlying neurobiological mechanisms are poorly understood. The use of antipsychotics and benzodiazepines against CIAPS is limited by side effects and/or by their ability to tackle only certain aspects of psychosis. Thus, safer wide-spectrum treatments are currently needed. Although the blockade of cannabinoid type-1 receptor (CB1) had been suggested as a therapeutical means against CIAPS, the use of orthosteric CB1 receptor full antagonists is strongly limited by undesired side effects and low efficacy. The neurosteroid pregnenolone has been recently shown to act as a potent endogenous allosteric signal-specific inhibitor of CB1 receptors. Thus, we tested in mice the potential therapeutic use of pregnenolone against acute psychotic-like effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis. We found that pregnenolone blocks a wide spectrum of THC-induced endophenotypes typically associated with psychotic-like states, including impairments in cognitive functions, somatosensory gating and social interaction. In order to capture THC-induced positive psychotic-like symptoms (e.g. perceptual delusions), we adapted a behavioral paradigm based on associations between different sensory modalities and selective devaluation, allowing the measurement of mental sensory representations in mice. Acting at hippocampal CB1 receptors, THC impaired the correct processing of mental sensory representations (reality testing) in an antipsychotic- and pregnenolone-sensitive manner. Overall, this work reveals that signal-specific inhibitors mimicking pregnenolone effects can be considered as promising new therapeutic tools to treat CIAPS.


Subject(s)
Pregnenolone/pharmacology , Psychoses, Substance-Induced/drug therapy , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Animals , Brain/metabolism , Cannabinoid Receptor Antagonists/therapeutic use , Cannabinoids/adverse effects , Cannabis/metabolism , Dronabinol/adverse effects , Male , Mental Disorders/drug therapy , Mice , Mice, Inbred C57BL , Pregnenolone/metabolism , Receptor, Cannabinoid, CB1/metabolism
3.
Neuroscience ; 323: 35-42, 2016 May 26.
Article in English | MEDLINE | ID: mdl-25967266

ABSTRACT

The endocannabinoid system is an important regulator of physiological functions. In the brain, this control is mainly exerted through the type-1-cannabinoid (CB1) receptors. CB1 receptors are abundant at neuron terminals where their stimulation inhibits neurotransmitter release. However, CB1 receptors are also expressed in astrocytes and recent studies showed that astroglial cannabinoid signaling is a key element of the tripartite synapse. In this review we discuss the different mechanisms by which astroglial CB1 receptors control synaptic transmission and plasticity. The recent involvement of astroglial CB1 receptors in the effects of cannabinoids on memory highlights their key roles in cognitive processes and further indicates that astrocytes are central active elements of high-order brain functions.


Subject(s)
Astrocytes/metabolism , Neurons/metabolism , Receptor, Cannabinoid, CB1/metabolism , Synapses/metabolism , Synaptic Transmission/physiology , Animals , Brain/metabolism , Humans , Memory, Short-Term/physiology , Neuronal Plasticity/physiology
4.
Neuropharmacology ; 99: 705-14, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26327678

ABSTRACT

The synthetic cannabinoid 1-pentyl-3-(1-naphthoyl)-indole (JWH-018) has been detected in about 140 samples of a smokable herbal mixture termed "Spice". JWH-018 is a CB1 and CB2 agonist with a higher affinity than Δ9-THC. In order to investigate the neurobiological substrates of JWH-018 actions, we studied by microdialysis in freely moving rats the effect of JWH-018 on extracellular dopamine (DA) levels in the nucleus accumbens (NAc) shell and core and in the medial prefrontal cortex (mPFC). JWH-018, at the dose of 0.25 mg/kg i.p., increased DA release in the NAc shell but not in the NAc core and mPFC. Lower (0.125 mg/kg) and higher doses (0.50 mg/kg) were ineffective. These effects were blocked by CB1 receptor antagonists (SR-141716A and AM 251) and were absent in mice lacking the CB1 receptor. Ex vivo whole cell patch clamp recordings from rat ventral tegmental area (VTA) DA neurons showed that JWH-018 decreases GABAA-mediated post-synaptic currents in a dose-dependent fashion suggesting that the stimulation of DA release observed in vivo might result from disinhibition of DA neurons. In addition, on the "tetrad" paradigm for screening cannabinoid-like effects (i.e., hypothermia, analgesia, catalepsy, hypomotility), JWH-018, at doses of 1 and 3 mg/kg i.p., produced CB1 receptor-dependent behavioural effects in rats. Finally, under appropriate experimental conditions, rats (20 µg/kg/inf i.v., FR3; nose-poking) and mice (30 µg/kg/inf i.v., FR1; lever-pressing) self-administer intravenously JWH-018. In conclusion, JWH-018 shares with the active ingredient of Marijuana, Δ9-THC, CB1-dependent reinforcing and DA stimulant actions.


Subject(s)
Cannabinoid Receptor Agonists/administration & dosage , Dopamine/metabolism , Indoles/administration & dosage , Naphthalenes/administration & dosage , Administration, Intravenous , Animals , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/physiology , Dose-Response Relationship, Drug , Inhibitory Postsynaptic Potentials/drug effects , Inhibitory Postsynaptic Potentials/physiology , Male , Mice, Inbred C57BL , Mice, Knockout , Microdialysis , Nucleus Accumbens/drug effects , Nucleus Accumbens/physiology , Patch-Clamp Techniques , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiology , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/metabolism , Receptors, GABA-A/metabolism , Self Administration , Species Specificity , Tissue Culture Techniques , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/physiology
5.
Neuroscience ; 263: 46-53, 2014 Mar 28.
Article in English | MEDLINE | ID: mdl-24434770

ABSTRACT

Cannabinoid receptor type 1 (CB1)-dependent signaling in the brain is known to modulate food intake. Recent evidence has actually shown that CB1 can both inhibit and stimulate food intake in fasting/refeeding conditions, depending on the specific neuronal circuits involved. However, the exact brain sites where this bimodal control is exerted and the underlying neurobiological mechanisms are not fully understood yet. Using pharmacological and electrophysiological approaches, we show that local CB1 blockade in the paraventricular nucleus of the hypothalamus (PVN) increases fasting-induced hyperphagia in rats. Furthermore, local CB1 blockade in the PVN also increases the orexigenic effect of the gut hormone ghrelin in animals fed ad libitum. At the electrophysiological level, CB1 blockade in slices containing the PVN potentiates the decrease of the activity of PVN neurons induced by long-term application of ghrelin. Hence, the PVN is (one of) the site(s) where signals associated with the body's energy status determine the direction of the effects of endocannabinoid signaling on food intake.


Subject(s)
Hyperphagia/physiopathology , Neurons/physiology , Paraventricular Hypothalamic Nucleus/physiology , Receptor, Cannabinoid, CB1/physiology , Animals , Cannabinoid Receptor Antagonists/pharmacology , Ghrelin/pharmacology , Male , Membrane Potentials/drug effects , Neurons/drug effects , Paraventricular Hypothalamic Nucleus/drug effects , Piperidines/pharmacology , Pyrazoles/pharmacology , Rats , Rats, Wistar , Receptor, Cannabinoid, CB1/antagonists & inhibitors
6.
Neuroscience ; 204: 230-44, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-21920410

ABSTRACT

This study has investigated the role of hypothalamic and amygdalar type-1 cannabinoid (CB1) receptors in the emotional and neuroendocrine responses to stress. To do so, we used the Cre/loxP system to generate conditional mutant mice lacking the CB1 gene in neurons expressing the transcription factor single-minded 1 (Sim1). This choice was dictated by former evidence for Sim1-Cre transgenic mice bearing Cre activity in all areas expressing Sim1, which chiefly includes the hypothalamus (especially the paraventricular nucleus, the supraoptic nucleus, and the posterior hypothalamus) and the mediobasal amygdala. Genomic DNA analyses in Sim1-CB1(-/-) mice indicated that the CB1 allele was excised from the hypothalamus and the amygdala, but not from the cortex, the striatum, the thalamus, the nucleus accumbens, the brainstem, the hippocampus, the pituitary gland, and the spinal cord. Double-fluorescent in situ hybridization experiments further indicated that Sim1-CB1(-/-) mice displayed a weaker CB1 receptor mRNA expression in the paraventricular nucleus of the hypothalamus and the mediobasal part of the amygdala, compared to wild-type animals. Individually housed Sim1-CB1(-/-) mice and their Sim1-CB1(+/+) littermates were exposed to anxiety and fear memory tests under basal conditions as well as after acute/repeated social stress. A principal component analysis of the behaviors of Sim1-CB1(-/-) and Sim1-CB1(+/+) mice in anxiety tests (open field, elevated plus-maze, and light/dark box) revealed that CB1 receptors from Sim1-expressing neurons exert tonic, albeit opposite, controls of locomotor and anxiety reactivity to novel environments. No difference between genotypes was observed during the recall of contextual fear conditioning or during active avoidance learning. Sim1-CB1(-/-), but not Sim1-CB1(+/+), mice proved sensitive to an acute social stress as this procedure reverted the increased ambulation in the center of the open field. The stimulatory influence of repeated social stress on body and adrenal weights, water intake, and sucrose preference was similar in the two genotypes. On the other hand, repeated social stress abolished the decrease in cued-fear conditioned expression that was observed in Sim1-CB1(-/-) mice, compared to Sim1-CB1(+/+) mice. This study suggests that CB1 receptors located on Sim1-expressing neurons exert a tonic control on locomotor reactivity, unconditioned anxiety, and cued-fear expression under basal conditions as well as after acute or repeated stress.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , Behavior, Animal/physiology , Brain/metabolism , Emotions/physiology , Neurons/metabolism , Receptor, Cannabinoid, CB1/metabolism , Repressor Proteins/metabolism , Animals , Anxiety/genetics , Anxiety/metabolism , Avoidance Learning/physiology , Basic Helix-Loop-Helix Transcription Factors/genetics , Conditioning, Psychological/physiology , Fear/physiology , Male , Memory/physiology , Mice , Mice, Transgenic , Motor Activity/physiology , Receptor, Cannabinoid, CB1/genetics , Repressor Proteins/genetics
7.
Int J Obes (Lond) ; 36(6): 880-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21844878

ABSTRACT

BACKGROUND: The endocannabinoid system is a potential pharmacotherapy target for obesity. However, the role of this system in human food intake regulation is currently unknown. METHODS: To test whether circulating endocannabinoids might functionally respond to food intake and verify whether these orexigenic signals are deregulated in obesity alongside with anorexigenic ones, we measured plasma anandamide (AEA), 2-arachidonoylglycerol (2-AG) and peptide YY (PYY) changes in response to a meal in 12 normal-weight and 12 non-diabetic, insulin-resistant obese individuals. RESULTS: Both normal-weight and obese subjects had a significant preprandial AEA peak. Postprandially, AEA levels significantly decreased in normal-weight, whereas no significant changes were observed in obese subjects. Similarly, PYY levels significantly increased in normal-weight subjects only. No meal-related changes were found for 2-AG. Postprandial AEA and PYY changes inversely correlated with waist circumference, and independently explained 20.7 and 21.3% of waist variance. Multiple regression analysis showed that postprandial AEA and PYY changes explained 34% of waist variance, with 8.2% of the variance commonly explained. CONCLUSION: These findings suggest that AEA might be a physiological meal initiator in humans and furthermore show that postprandially AEA and PYY are concomitantly deregulated in obesity.


Subject(s)
Appetite Regulation/drug effects , Arachidonic Acids/blood , Cannabinoid Receptor Modulators/blood , Endocannabinoids , Glycerides/blood , Obesity/blood , Obesity/drug therapy , Peptide YY/blood , Polyunsaturated Alkamides/blood , Adult , Body Mass Index , Eating/drug effects , Female , Humans , Insulin Resistance , Male , Peptide YY/drug effects , Postprandial Period
8.
Genes Brain Behav ; 8(7): 685-98, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19563475

ABSTRACT

To investigate the impact of averseness, controllability and familiarity of a test situation on the involvement of the endocannabinoid system in the regulation of exploratory behaviour, we tested conventional and conditional cannabinoid receptor type 1 (CB1)-deficient mice in behavioural paradigms with different emotional load, which depended on the strength of illumination and the ability of the animals to avoid the light stimulus. Complete CB1 null-mutant mice (Total-CB1-KO) showed an anxiogenic-like phenotype under circumstances where they were able to avoid the bright light such as the elevated plus-maze and the light/dark avoidance task. Conditional mutant mice lacking CB1 expression specifically in cortical glutamatergic neurons (Glu-CB1-KO), in contrast, failed to show a similar phenotype under the same experimental conditions. However, both mutant lines showed increased avoidance of open arm exploration during a second exposure to the elevated plus-maze. If tested in situations where the fear eliciting light could not be avoided, Total-CB1-KO mice showed increased thigmotaxis in an open field, decreased social investigation and decreased novel object exploration under aversive light conditions, but not under non-aversive low light. This time, Glu-CB1-KO also showed decreased exploratory behaviour towards objects and conspecific juveniles and increased thigmotaxis in the open field. Taking into consideration that the behavioural performance of wild-type mice was only marginally affected by changes in light intensities, these data indicate that the endocannabinoid system renders exploratory behaviour largely independent of the test averseness. This process differentially involves endocannabinoid-controlled glutamatergic transmission, depending on the controllability of the test situation.


Subject(s)
Avoidance Learning/physiology , Cannabinoid Receptor Modulators/metabolism , Endocannabinoids , Exploratory Behavior/physiology , Fear/physiology , Glutamic Acid/metabolism , Receptor, Cannabinoid, CB1/genetics , Animals , Behavior, Animal/physiology , Brain Chemistry/genetics , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Male , Maze Learning/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Neuropsychological Tests , Phenotype , Photophobia/genetics , Photophobia/metabolism , Photophobia/physiopathology , Synaptic Transmission/genetics
9.
Genes Brain Behav ; 8(2): 203-11, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19077175

ABSTRACT

Recent evidence showed that the endocannabinoid system plays an important role in the behavioral adaptation of stress and fear responses. In this study, we chose a behavioral paradigm that includes criteria of both fear and stress responses to assess whether the involvement of endocannabinoids in these two processes rely on common mechanisms. To this end, we delivered a footshock and measured the fear response to a subsequently presented novel tone stimulus. First, we exposed different groups of cannabinoid receptor type 1 (CB(1))-deficient mice (CB(1) (-/-)) and their wild-type littermates (CB(1) (+/+)) to footshocks of different intensities. Only application of an intense footshock resulted in a sustained fear response to the tone in CB(1) (-/-). Using the intense protocol, we next investigated whether endocannabinoids mediate their effects via an interplay with corticotropin-releasing hormone (CRH) signaling. Pharmacological blockade of CB(1) receptors by rimonabant in mice deficient for the CRH receptor type 1 (CRHR1(-/-)) or type 2 (CRHR2(-/-)), and in respective wild-type littermates, resulted in a sustained fear response in all genotypes. This suggests that CRH is not involved in the fear-alleviating effects of CB(1). As CRHR1(-/-) are known to be severely impaired in stress-induced corticosterone secretion, our observation also implicates that corticosterone is dispensable for CB(1)-mediated acute fear adaptation. Instead, conditional mutants with a specific deletion of CB(1) in principal neurons of the forebrain (CaMK-CB(1) (-/-)), or in cortical glutamatergic neurons (Glu-CB(1) (-/-)), showed a similar phenotype as CB(1) (-/-), thus indicating that endocannabinoid-controlled glutamatergic transmission plays an essential role in acute fear adaptation.


Subject(s)
Adaptation, Psychological/physiology , Cannabinoid Receptor Modulators/physiology , Corticotropin-Releasing Hormone/physiology , Endocannabinoids , Fear/physiology , Glutamates/physiology , Neurons/physiology , Acoustic Stimulation , Animals , Electroshock , Fear/psychology , Male , Mice , Mice, Knockout , Piperidines/pharmacology , Prosencephalon/cytology , Prosencephalon/physiology , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/physiology , Receptors, Corticotropin-Releasing Hormone/genetics , Receptors, Corticotropin-Releasing Hormone/physiology , Receptors, Glutamate/genetics , Receptors, Glutamate/physiology , Rimonabant , Signal Transduction/physiology
10.
Pharmacogenomics J ; 8(3): 196-208, 2008 Jun.
Article in English | MEDLINE | ID: mdl-17684478

ABSTRACT

Dysregulation of the endocannabinoid system is known to interfere with emotional processing of stressful events. Here, we studied the role of cannabinoid receptor type 1 (CB1) signaling in stress-coping behaviors using the forced swim test (FST) with repeated exposures. We compared effects of genetic inactivation with pharmacological blockade of CB1 receptors both in male and female mice. In addition, we investigated potential interactions of the endocannabinoid system with monoaminergic and neurotrophin systems of the brain. Naive CB1 receptor-deficient mice (CB1-/-) showed increased passive stress-coping behaviors as compared to wild-type littermates (CB1+/+) in the FST, independent of sex. These findings were partially reproduced in C57BL/6N animals and fully reproduced in female CB1+/+ mice by pharmacological blockade of CB1 receptors with the CB1 receptor antagonist SR141716. The specificity of SR141716 was confirmed in female CB1-/- mice, where it failed to affect behavioral performance. Sensitivity to the antidepressants desipramine and paroxetine was preserved, but slightly altered in female CB1-/- mice. There were no genotype differences between CB1+/+ and CB1-/- mice in monoamine oxidase A and B activities under basal conditions, nor in monoamine content of hippocampal tissue after FST exposure. mRNA expression of vesicular glutamate transporter type 1 was unaffected in CB1-/- mice, but mRNA expression of brain-derived neurotrophic factor (BDNF) was reduced in the hippocampus. Our results suggest that impaired CB1 receptor function promotes passive stress-coping behavior, which, at least in part, might relate to alterations in BDNF function.


Subject(s)
Adaptation, Psychological , Receptor, Cannabinoid, CB1/physiology , Signal Transduction/physiology , Stress, Psychological/psychology , Animals , Biogenic Monoamines/analysis , Brain-Derived Neurotrophic Factor/genetics , Desipramine/pharmacology , Female , Hippocampus/chemistry , Male , Mice , Mice, Inbred C57BL , Monoamine Oxidase/metabolism , Piperidines/pharmacology , Pyrazoles/pharmacology , RNA, Messenger/analysis , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/genetics , Rimonabant , Swimming , Vesicular Glutamate Transport Protein 1/genetics
11.
Neurogastroenterol Motil ; 19(9): 744-53, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17727394

ABSTRACT

Cannabinoid-1 (CB1) receptor activation affects gastrointestinal propulsion in vivo. It was our aim to further characterize the involved myenteric mechanisms in vivo and in vitro. In CB1(-/-) mice and wild-type littermates we performed in vivo transit experiments by charcoal feeding and in vitro electrophysiological recordings in mouse small intestinal smooth muscle. Ascending neuronal contraction (ANC) following electrical field stimulation was studied in rat ileum in a partitioned organ bath separating the aboral stimulation site from the oral recording site. The knockout animals displayed an accelerated upper gastrointestinal transit compared to control animals. The CB1 receptor antagonist AM251 stimulated the force of the ANC in a concentration dependent manner when added in the oral chamber. Anandamide significantly inhibited the ANC when added in the oral chamber. Neither AM251 nor anandamide had an influence on the contraction latency. No effects were observed when drugs were added in the aboral chamber, proving a CB1 mediated action on the neuromuscular junction. Resting membrane potentials and neuronal induced inhibitory junction potentials in CB1(-/-) mice were unchanged as compared to wild type. However, the electrophysiological slow waves were more sensitive to blockade of Ca(2+) channels in CB1(-/-) mice. Our data strongly suggest a physiological involvement of the CB-1 receptor in the regulation of small intestinal motility. Therefore, CB1 receptors are a promising target for the treatment of motility disorders.


Subject(s)
Intestinal Mucosa/metabolism , Myoelectric Complex, Migrating/physiology , Peristalsis/physiology , Receptor, Cannabinoid, CB1/metabolism , Animals , Arachidonic Acids/pharmacology , Cannabinoid Receptor Modulators/pharmacology , Electric Stimulation , Endocannabinoids , Intestines/innervation , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Mice, Knockout , Muscle, Smooth/drug effects , Muscle, Smooth/metabolism , Myoelectric Complex, Migrating/drug effects , Neuromuscular Junction/drug effects , Neuromuscular Junction/metabolism , Organ Culture Techniques , Peristalsis/drug effects , Piperidines/pharmacology , Polyunsaturated Alkamides/pharmacology , Pyrazoles/pharmacology , RNA, Messenger/analysis , Rats , Rats, Wistar , Reflex/drug effects , Reflex/physiology , Reverse Transcriptase Polymerase Chain Reaction
12.
Neuroscience ; 146(3): 1212-9, 2007 May 25.
Article in English | MEDLINE | ID: mdl-17383106

ABSTRACT

The endocannabinoid system (ECS) possesses neuromodulatory functions by influencing the release of various neurotransmitters, including GABA, noradrenaline, dopamine, glutamate and acetylcholine. Even though there are studies indicating similar interactions between the ECS and the serotonergic system, there are no results showing clear evidence for type 1 cannabinoid receptor (CB1) location on serotonergic neurons. In this study, we show by in situ hybridization that a low but significant fraction of serotonergic neurons in the raphe nuclei of mice contains CB1 mRNA as illustrated by the coexpression with the serotonergic marker gene tryptophane hydroxylase 2, the rate limiting enzyme for the serotonin synthesis. Furthermore, by double immunohistochemistry and confocal microscopy, we were able to detect CB1 protein on serotonergic fibers and synapses expressing the serotonin uptake transporter in the hippocampus and the amygdala. Our findings indicate that the CB1-mediated regulation of serotonin release can depend in part on a direct cross-talk between the two systems at single cell level, which might lead to functional implications in the modulation of emotional states.


Subject(s)
Raphe Nuclei/cytology , Raphe Nuclei/metabolism , Receptor, Cannabinoid, CB1/metabolism , Serotonin/physiology , Amygdala/cytology , Amygdala/metabolism , Animals , Dentate Gyrus/cytology , Dentate Gyrus/metabolism , Female , Genetic Markers , Hippocampus/cytology , Hippocampus/metabolism , Immunohistochemistry , In Situ Hybridization , Isoenzymes/genetics , Mice , Mice, Inbred C57BL , Microscopy, Confocal , Nerve Fibers/metabolism , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Serotonin Plasma Membrane Transport Proteins/metabolism , Synapses/metabolism , Tryptophan Hydroxylase/genetics
13.
J Endocrinol Invest ; 29(3 Suppl): 27-46, 2006.
Article in English | MEDLINE | ID: mdl-16751707

ABSTRACT

The endocannabinoid system (ECS) has recently emerged as an important neuromodulatory system in the brain. Several neuronal functions are under the control of the cannabinoid receptor type 1 (CB1 receptor) and of its endogenous lipid ligands (endocannabinoids). CB1 receptors are widely expressed in the brain and their expression pattern reflects the complexity and the variety of functions of the ECS in neuronal activity. In particular, CB1 receptors are present at different levels in several brain regions and in distinct neuronal subpopulations. Endocannabinoids were described to act as retrograde transmitters at synaptic level in many brain regions. Interestingly, the mechanisms governing endocannabinoid-controlled synaptic modulation can vary depending on the region and the neuronal circuit. At physiological and pathophysiological level, the ECS has recently been shown to play important regulatory roles in several brain processes, including the modulation of memory processing and the control of excessive neuronal activity. The discovery of the ECS represents a hallmark in neuroscience research, and the exploitation of its numerous physiological and pathophysiological functions is a promising avenue for therapeutic applications.


Subject(s)
Brain Chemistry/physiology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Neurotransmitter Agents/physiology , Receptor, Cannabinoid, CB1/physiology , Animals , Humans
14.
Int J Obes (Lond) ; 30 Suppl 1: S39-43, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16570104

ABSTRACT

The promising results obtained by clinical trials using Rimonabant to tackle visceral obesity and related disorders recently promoted a remarkable impulse to carry out detailed investigations into the mechanisms of action of endocannabinoids in regulating food intake and energy metabolism. The endocannabinoid system has been known for many years to play an important role in the modulation of the neuronal pathways mediating the rewarding properties of food. However, in the last few years, with the advanced understanding of the crucial role of the hypothalamic neuronal network in the regulation of appetite, several studies have also directed attention to the orexigenic role of the endocannabinoid system, substantiating the well known appetite stimulating properties of derivatives of Cannabis sativa. Furthermore, the last 2 years have seen a number of relevant publications emphasizing the role of endocannabinoids as significant players in various peripheral metabolic processes. To date, the roles of the endocannabinoid system in influencing energy metabolism have proved to be more complex than was formerly believed. However, the diverse ability to modulate both central and peripheral processes highlights the pivotal involvement of the endocannabinoid system in the control of metabolic processes. This review describes the roles of endocannabinoids and the cannabinoid type 1 receptor (CB1) in the control of energy balance.


Subject(s)
Adipose Tissue/metabolism , Brain/metabolism , Cannabinoid Receptor Modulators/metabolism , Endocannabinoids , Energy Metabolism , Liver/metabolism , Animals , Appetite Regulation , Fatty Acids/biosynthesis , Humans , Hypothalamus/metabolism , Leptin/metabolism , Receptor, Cannabinoid, CB1/metabolism
15.
J Mol Med (Berl) ; 84(6): 513-20, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16501934

ABSTRACT

CB1 and TRPV1 receptors modulate enteric neurotransmission and colonic inflammation. This study investigates early electrophysiological changes in distal colon of wild-type and receptor deficient mice after an inflammatory insult set by dinitrobenzene sulfonic acid (DNBS). Colitis was induced by DNBS in CB1(-/-) mice, TRPV1(-/-) mice, and their respective wild-type littermates. Electrophysiological properties consisting of membrane potentials and electrically induced inhibitory junction potentials (IJP) of circular smooth muscle cells were evaluated at different time points. Additionally a histological colitis severity score was evaluated in CB1(+/+) and CB1(-/-) mice 24 h after DNBS. Inflammation caused spontaneous atropine insensitive rhythmic action potentials in CB1(-/-) and TRPV1(-/-) mice but not in wild-type animals. This indicates that membrane stability is disturbed, which in turn indicates a lack of protective mechanisms. Focal electrical neuronal stimulation of the myenteric plexus induced IJP in the smooth muscle cells. Twenty-four hours after initiation of inflammation, the duration of the IJP is prolonged in all animals, indicating disturbances within neuromuscular interaction. In CB1(-/-) mice, it is interesting that the duration of IJP was significantly extended, as compared to CB1(+/+) mice pointing toward missing protective mechanisms in the CB1(-/-) mice. Inflammatory insults in the mouse colon induce reproducible changes in the electrophysiological properties and such changes correlate with duration of colitis. In mutants, these electrophysiological changes display different patterns, suggesting the lack of protective properties for neuromuscular interactions and membrane stability.


Subject(s)
Colon/physiopathology , Myocytes, Smooth Muscle/physiology , Receptor, Cannabinoid, CB1/physiology , TRPV Cation Channels/physiology , Action Potentials , Animals , Benzenesulfonates , Colitis/chemically induced , Colitis/physiopathology , Colon/innervation , Electric Stimulation , Female , Membrane Potentials , Mice , Mice, Knockout , Myenteric Plexus/physiology , Neuromuscular Junction/physiology , Receptor, Cannabinoid, CB1/genetics , TRPV Cation Channels/genetics
16.
J Mol Med (Berl) ; 84(2): 142-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16389550

ABSTRACT

In the human colon, vanilloid receptor TRPV1 is overexpressed both in afferent nerve terminals and in epithelial cells during inflammation. In the past years, pharmacological experiments using TRPV1 agonists and antagonists revealed that TRPV1 receptors may play proinflammatory and protective roles in the gastrointestinal tract. Here, we applied a genetic approach to define the role of TRPV1 and analyzed the effects of dinitrobenzene sulfonic acid (DNBS)-induced colitis in TRPV1-deficient (TRPV1-/-) mice. Intrarectal infusion of DNBS induced increased inflammation in TRPV1-/- mice compared to wild-type littermates (TRPV1+/+) as evaluated by macroscopic scoring and myeloperoxidase assays. This finding indicates that TRPV1 receptors are required for the protection within sensory pathways that regulate the response following the initiation of colonic inflammation. Electrophysiological recordings from circular smooth-muscle cells, performed 8 and 24 h after DNBS treatment, revealed strong spontaneous oscillatory action potentials in TRPV1-/- but not in TRPV1+/+ colons, indicating an early TRPV1-mediated control of inflammation-induced irritation of smooth-muscle activities. These unexpected results suggest that TRPV1 receptors mediate endogenous protection against experimentally induced colonic inflammation.


Subject(s)
Benzenesulfonates/toxicity , Colitis/chemically induced , Colitis/genetics , Genetic Predisposition to Disease , TRPV Cation Channels/deficiency , TRPV Cation Channels/genetics , Animals , Female , Mice , Mice, Knockout , Severity of Illness Index , TRPV Cation Channels/physiology
17.
Am J Physiol Gastrointest Liver Physiol ; 286(1): G110-7, 2004 Jan.
Article in English | MEDLINE | ID: mdl-12893627

ABSTRACT

The effects of cannabinoid receptor agonists and antagonists on smooth muscle resting membrane potentials and on membrane potentials following electrical neuronal stimulation in a myenteric neuron/smooth muscle preparation of wild-type and cannabinoid receptor type 1 (CB1)-deficient mice were investigated in vitro. Double staining for CB1 and nitric oxide synthase (neuronal) was performed to identify the myenteric CB1-expressing neurons. Focal electrical stimulation of the myenteric plexus induced a fast (f) excitatory junction potential (EJP) followed by a fast and a slow (s) inhibitory junction potential (IJP). Treatment of wild-type mice with the endogenous CB1 receptor agonist anandamide reduced EJP while not affecting fIJP and sIJP. EJP was significantly higher in CB1-deficient mice than in wild-type littermate controls, and anandamide induced no effects in CB1-deficient mice. N-arachidonoyl ethanolamide (anandamide), R-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3,-de]- 1,4-benzoxazin-6-yl]-1-naphtalenylmethanone, a synthetic CB1 receptor agonist, nearly abolished EJP and significantly reduced the fIJP in wild-type mice. N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-caroxamide (SR141716A), a CB1-specific receptor antagonist, was able to reverse the agonist effects induced in wild-type mice. SR141716A, when given alone, significantly increased EJP in wild-type mice without affecting IJP in wild-type and EJP in CB1-deficient mice. Interestingly, SR141716A reduced fIJP in CB1-deficient mice. In the mouse colon, nitrergic myenteric neurons do not express CB1, implying that CB1 is expressed in cholinergic neurons, which is in line with the functional data. Finally, excitatory and inhibitory neurotransmission in the mouse colon is modulated by activation of CB1 receptors. The significant increase in EJP in CB1-deficient mice strongly suggests a physiological involvement of CB1 in excitatory cholinergic neurotransmission.


Subject(s)
Colon/innervation , Receptor, Cannabinoid, CB1/physiology , Synaptic Transmission/physiology , Animals , Arachidonic Acids/pharmacology , Benzoxazines , Colon/physiology , Electric Stimulation , Electrophysiology , Endocannabinoids , Female , Immunohistochemistry , Membrane Potentials/drug effects , Mice , Mice, Inbred C57BL , Morpholines/pharmacology , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Myenteric Plexus/cytology , Myenteric Plexus/drug effects , Naphthalenes/pharmacology , Neuromuscular Junction/drug effects , Neurons/drug effects , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Piperidines/pharmacology , Polyunsaturated Alkamides , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Rimonabant
18.
Int J Obes Relat Metab Disord ; 27(3): 289-301, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12629555

ABSTRACT

The ability of Cannabis sativa (marijuana) to increase hunger has been noticed for centuries, although intensive research on its molecular mode of action started only after the characterization of its main psychoactive component Delta(9)-tetrahydrocannabinol in the late 1960s. Despite the public concern related to the abuse of marijuana and its derivatives, scientific studies have pointed to the therapeutic potentials of cannabinoid compounds and have highlighted their ability to stimulate appetite, especially for sweet and palatable food. Later, the discovery of specific receptors and their endogenous ligands (endocannabinoids) suggested the existence of an endogenous cannabinoid system, providing a physiological basis for biological effects induced by marijuana and other cannabinoids. Epidemiological reports describing the appetite-stimulating properties of cannabinoids and the recent insights into the molecular mechanisms underlying cannabinoid action have proposed a central role of the cannabinoid system in obesity. The aim of this review is to provide an extensive overview on the role of this neuromodulatory system in feeding behavior by summarizing the most relevant data obtained from human and animal studies and by elucidating the interactions of the cannabinoid system with the most important neuronal networks and metabolic pathways involved in the control of food intake. Finally, a critical evaluation of future potential therapeutical applications of cannabinoid antagonists in the therapy of obesity and eating disorders will be discussed.


Subject(s)
Appetite Regulation/physiology , Eating/physiology , Fatty Acids, Unsaturated/physiology , Animals , Cannabinoid Receptor Modulators , Cannabinoids/antagonists & inhibitors , Cannabinoids/therapeutic use , Feeding Behavior/physiology , Humans , Mice , Obesity/drug therapy
19.
Neuroscience ; 109(3): 451-60, 2002.
Article in English | MEDLINE | ID: mdl-11823058

ABSTRACT

The cannabinoid receptor type 1 (CB1) displays unusual properties, including the dual capacity to inhibit or stimulate adenylate cyclase and a brain density considerably higher than the majority of G protein-coupled receptors. Together with overlapping expression patterns of dopamine and serotonin receptors this suggests a potential of CB1 to modulate the function of the dopamine and serotonin system. Indeed, pharmacological studies provide evidence for cross-talks between CB1 and receptors of these neurotransmitter systems. In trying to obtain further insights into possible functional and/or structural interactions between CB1 and the dopamine receptors and the serotonin receptors, we performed double-label in situ hybridization at the cellular level on mouse forebrain sections by combining a digoxigenin-labelled riboprobe for CB1 with 35S-labelled riboprobes for dopamine receptors D1 and D2, and for serotonin receptors 5-HT1B and 5-HT3, respectively. As a general rule, we found that CB1 colocalizes with D1, D2 and 5-HT1B only in low-CB1-expressing cells which are principal projecting neurons, whereas CB1 coexpression with 5-HT3 was also observed in high-CB1-expressing cells which are considered to be mostly GABAergic. In striatum and olfactory tubercle, CB1 is coexpressed to a high extent with D1, D2 and 5-HT1B. Throughout the hippocampal formation, CB1 is coexpressed with D2, 5-HT1B and 5-HT3. In the neocortex, coexpression was detected only with 5-HT1B and 5-HT3. In summary a distinct pattern is emerging for the cannabinoid system with regard to its colocalization with dopamine and serotonin receptors and, therefore, it is likely that different mechanisms underlie its cross-talk with these neurotransmitter systems.


Subject(s)
Cannabinoids/metabolism , Neurons/metabolism , Prosencephalon/metabolism , Receptors, Dopamine/genetics , Receptors, Drug/genetics , Receptors, Serotonin/genetics , Synaptic Transmission/physiology , Animals , Cannabinoids/pharmacology , Dopamine/metabolism , In Situ Hybridization , Mice , Mice, Inbred C57BL , Neurons/cytology , Prosencephalon/cytology , RNA, Messenger/metabolism , Receptor, Serotonin, 5-HT1B , Receptors, Cannabinoid , Receptors, Dopamine D1/genetics , Receptors, Dopamine D2/genetics , Receptors, Serotonin, 5-HT3 , Serotonin/metabolism
20.
J Clin Endocrinol Metab ; 86(6): 2687-96, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11397872

ABSTRACT

Little is known about the expression and function of cannabinoid receptor type 1 (CB1) in the human pituitary gland. The aim of this study was to investigate CB1 expression in human normal and tumoral pituitaries by in situ hybridization and immunohistochemistry using an antibody against CB1. CB1 was found in corticotrophs, mammotrophs, somatotrophs, and folliculostellate cells in the anterior lobe of normal pituitary. After examination of 42 pituitary adenomas, CB1 was detected in acromegaly-associated pituitary adenomas, Cushing's adenomas, and prolactinomas, whereas faint or no expression was found in nonfunctioning pituitary adenomas. Experiments with cultured pituitary adenoma cells showed that the CB1 agonist WIN 55,212--2 inhibited GH secretion in most of acromegaly-associated pituitary adenomas tested and that the CB1 antagonist SR 141716A was generally able to reverse this effect. Moreover, WIN 55,212--2 was able to suppress GHRH-stimulated GH release, and this effect was not blocked by coincubation with SR 141716A, possibly indicating a non-CB1-mediated effect. In contrast, WIN 55,212--2 was ineffective on GH-releasing peptide-stimulated GH release. In four Cushing's adenomas tested, WIN 55,212--2 was not able to modify basal ACTH secretion. However, simultaneous application of CRF and WIN 55,212--2 resulted in a synergistic effect on ACTH secretion, and this effect could be abolished by SR 141716A, demonstrating a CB1-mediated effect. In the single case of prolactinomas tested, WIN 55,212--2 was able to inhibit basal secretion of PRL. Finally, the presence of endocannabinoids (anandamide and 2-arachidonoylglycerol) was investigated in normal and tumoral pituitaries. All tumoral samples had higher contents of anandamide and 2-arachidonoylglycerol compared with the normal hypophysis. Moreover, endocannabinoid content in the different pituitary adenomas correlated with the presence of CB1, being elevated in the tumoral samples positive for CB1 and lower in the samples in which no or low levels of CB1 were found. The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion.


Subject(s)
Adenoma/metabolism , Cannabinoids/biosynthesis , Pituitary Gland/metabolism , Pituitary Neoplasms/metabolism , Receptors, Drug/metabolism , Adenoma/pathology , Adolescent , Adult , Aged , Cannabinoid Receptor Modulators , Cannabinoids/metabolism , Cannabinoids/pharmacology , Female , Hormones/metabolism , Humans , Male , Middle Aged , Pituitary Neoplasms/pathology , Receptors, Cannabinoid , Reference Values , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...